Nuvaxovid XBB.1.5

Nuvaxovid XBB.1.5 (NVX-CoV2601) is a monovalent, protein-based COVID-19 vaccine developed by Novavax. It is an updated 2023-2024 formulation specifically engineered to target the SARS-CoV-2 Omicron XBB.1.5 subvariant. The vaccine contains a recombinant version of the spike (S) protein of the virus, produced in insect cells using a baculovirus expression system, and is adjuvanted with Matrix-M, a saponin-based substance that enhances the immune response. Upon administration, the vaccine triggers the production of neutralizing antibodies and activates T-cell responses against the spike protein, thereby preventing the virus from entering human cells. It is indicated for active immunization to prevent COVID-19 in individuals aged 12 years and older and is administered as an intramuscular injection.

Brand names

Nuvaxovid

Other names

Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula)SARS-CoV-2 rS (XBB.1.5)Nuvaxovid XBB.1.5-Novavax-COVID-19